Barriers for the development, translation, and implementation of nanomedicine: an African perspective

Muthupandian Saravanan; Balajee Ramachandran; Barabadi Hamed; Marco Giardiello

doi:10.1002/jin2.43

journal article Open Access Jun 27, 2018

Barriers for the development, translation, and implementation of nanomedicine: an African perspective

Muthupandian Saravanan Balajee Ramachandran Barabadi Hamed Marco Giardiello

Journal of Interdisciplinary Nanomedicine Vol. 3 No. 3 pp. 106-110 · Wiley

View at Publisher Save 10.1002/jin2.43

Abstract

AbstractNanotechnology is a branch of science, which empowers innovation to discover new medical technologies, improving current diagnostic and treatment methods. The scope of nanotechnology focuses mainly on “technology transfer”, in which research aims to facilitate the application of recent nanoscience techniques to conventional medicine development methodologies. Nanomedicine is attractive to researchers who wish to target specific infectious diseases associated with poverty, which is highlighted through the many pertinent examples of recent breakthroughs in nanomedicine. An overview is provided in this study to highlight the barriers and implementation of nanomedicine for various infectious diseases in the African continent. Patient backgrounds provide the greatest of challenges for new technologies in terms of improving bioavailability and dosage. This review points out the current situation of nanomedicine in Africa and explores the possibility of how nanomedicine could improve patient drug regimens and wellbeing.

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

Gordon L. Amidon, Hans Lennernäs, Vinod P. Shah et al.

Pharmaceutical Research 10.1023/a:1016212804288

[2]

10.1185/146300902322125091

[3]

Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: a comparative study

Ameer Azam, Ahmed, Oves et al.

International Journal of Nanomedicine 10.2147/ijn.s35347

[4]

10.14715/cmb/2017.63.12.2

[5]

10.1080/17518253.2017.1385856

[6]

10.2147/ijn.s76501

[7]

10.1016/j.bbrc.2015.10.136

[8]

10.1016/j.colsurfb.2011.05.025

[9]

10.1016/j.jconrel.2015.01.035

[10]

10.1016/j.taap.2008.06.009

[11]

Drug delivery and nanoparticles: Applications and hazards

de Jong

International Journal of Nanomedicine 10.2147/ijn.s596

[12]

10.1093/clinids/22.6.938

[13]

10.1016/j.nano.2012.05.013

[14]

10.1007/978-1-59745-483-4_27

[15]

Personalized Nanomedicine: A Revolution at the Nanoscale

Cristina Fornaguera, Maria García-Celma

Journal of Personalized Medicine 10.3390/jpm7040012

[16]

10.1038/ncomms13184

[17]

WHO (2010)

[18]

Clinical development success rates for investigational drugs

Michael Hay, David W Thomas, John L Craighead et al.

Nature Biotechnology 10.1038/nbt.2786

[19]

10.1016/j.clinbiochem.2012.12.020

[20]

10.1016/s0169-409x(01)00152-1

[21]

10.1016/j.msec.2013.07.013

[22]

10.1016/j.actatropica.2017.02.019

[23]

10.1016/j.tiv.2015.04.021

[24]

10.1039/c2cs15344k

[25]

10.1111/bph.12421

[26]

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer

Yogeshkumar Malam, Marilena Loizidou, Alexander M. Seifalian

Trends in Pharmacological Sciences 10.1016/j.tips.2009.08.004

[27]

10.1021/bc800057g

[28]

10.1016/b978-0-444-62747-6.00007-5

[29]

Meerovich G. Meerovich G.I. Evgeniy A. L. NataliaO. Valentina M.D. Smirnova Z.V. Pevgov V. Zorin A.B. Dimitri G. Loschenov V. Vorozhtsov G. N. Baryshnikov A.2008.Influence of liposome size on accumulation in tumor and therapeutic efficiency of liposomal near‐IR photosensitizer for PDT based on aluminum hydroxide tetra‐3‐phenylthiophthalocyanine. NSTI Nanotech 2008 Technical Proceedings. 2:41–44.

[30]

Navalakhe R. M. "Application of nanotechnology in biomedicine" Indian J. Exp. Biol. (2007)

[31]

10.3389/fcimb.2013.00089

[32]

10.2478/v10039-012-0031-9

[33]

Nanodrugs: pharmacokinetics and safety

Satomi Onoue, Shizuo Yamada, Kim Chan

International Journal of Nanomedicine 10.2147/ijn.s38378

[34]

10.1002/ijc.27528

[35]

10.2174/2211738506666180209095710

[36]

UNAIDS report on the global AIDS epidemic 2010 UNAIDS

[37]

10.1038/nbt1006-1211

[38]

10.1002/smll.201100442

[39]

10.2147/nano.2006.1.2.115

[40]

WHO World Malaria Report 2010 2010.World Health Organisation (WHO) Geneva.

Metrics

10

Citations

40

References

Details

Published: Jun 27, 2018
Vol/Issue: 3(3)
Pages: 106-110
License: View

Authors

M

Muthupandian Saravanan

Department of Medical Microbiology and Immunology, School of Medicine, College of Health Science Mekelle University Mekelle 1871 Ethiopia

B

Balajee Ramachandran

Department of Chemistry University of Southern California USA 90089

B

Barabadi Hamed

Department of Pharmaceutical Biotechnology, School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran Iran

M

Marco Giardiello

Department of Chemistry University of Liverpool UK

Cite This Article

Muthupandian Saravanan, Balajee Ramachandran, Barabadi Hamed, et al. (2018). Barriers for the development, translation, and implementation of nanomedicine: an African perspective. Journal of Interdisciplinary Nanomedicine, 3(3), 106-110. https://doi.org/10.1002/jin2.43